Corxel Pharmaceuticals is preparing to go public through a SPAC merger, targeting a new funding pathway as it advances an oral GLP-1–based obesity program toward Phase 3. The company’s announcement pairs two GLP-1 and amylin-targeting medicines with a planned closing in the first half of 2027. The move underscores how late-stage oral incretin contenders are seeking additional capital runway for pivotal execution and manufacturing readiness, particularly as competition intensifies across GLP-1 and dual agonist portfolios. Investors and development teams will watch whether Corxel’s structure can translate preclinical and early clinical differentiation into Phase 3 endpoints—and how it manages regulatory expectations around oral exposure and tolerability.